Associate Professor, Laboratory Medicine, University of Washington School of Medicine
Pediatrics
Dr. Chihiro C. Morishima, MD
|
|
Give Review
Chihiro Morishima works in the field of Pediatrics. Chihiro Morishima has written publications. He has 50 publications published with PubMed. The lastest publication is: 'Severe drug-induced pneumonitis associated with minocycline and nicotinamide therapy of a bullous pemphigoid.' He is registered with Medicare and accepts Medicare payments.
Publications
- Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection.
- Dietary Cholesterol Intake is Associated with Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the HALT-C trial.
- Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
- Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C.
- A summary of the 18th International Symposium on Hepatitis C Virus and Related Viruses.
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
- Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
- Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.
- Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
- Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
- Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.
- Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
- Identification of hepatoprotective flavonolignans from silymarin.
- Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.
- Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.
- Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.
- Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.
- Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
- Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
- Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
- Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
- Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
- Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepati...
- Antiviral effects of silymarin against hepatitis C: the jury is still out.
- Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
- Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapy.
- Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection.
- Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.
- Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
- Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
- Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
- HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
- Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
- Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.
- High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection.
- Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
- Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.
- Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.
- Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
- Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.
- Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
- Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.
- Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.
- Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study.
- Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy.
- Severe drug-induced pneumonitis associated with minocycline and nicotinamide therapy of a bullous pemphigoid.
- Expression of two structurally identical viral superantigens results in thymic elimination at distinct developmental stages.
- Structural requirements for sulfation of asparagine-linked oligosaccharides of lutropin.
- Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model.
Schools
Washington Univ Sch Of Med
Doctors Specialties
- Pediatric Rheumatology
- Pediatrics
Accepted Insurances
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295077287 |
| Last Name Of The Provider | MORISHIMA |
| First Name Of The Provider | CHIHIRO |
| View All |
Similar Doctors
|
|
Dr. Faranek Davalian, MD |
|
|
Dr. Jill K. Allen, MD |
|
|
Dr. Sarah H. Perry, MD |
|
|
Dr. Kyle E. Yasuda, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula Lozano, MD |
|
|
Dr. Sheryl A. Morelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catharine C. Eleey, MD |
|
|
Dr. Vanessa M. Pineros, MD |
|
|
Dr. Sarah H. Zaman, MD |
|
|
Dr. Stuart J. Kahn, MD
This Doctor is OpenDoctor Recommended.
|